Vycor Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
March 31, 2021 at 02:40 pm EDT
Share
Vycor Medical, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 1.142 million compared to USD 1.392 million a year ago. Operating loss was USD 727,394 compared to USD 601,393 a year ago. Net loss was USD 822,482 compared to USD 796,202 a year ago. Basic loss per share was USD 0.04 compared to USD 0.05 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.03 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
